Yalong Dang

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Current drug targets

F1000Research

Oxidative medicine and cellular longevity

Medicine

University of Pittsburgh

Zhengzhou University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Pittsburgh Nov 01 2015 - Nov 01 2017

United States

Postdoc Associate :: Department of Ophthalmology

University of Hong Kong May 15 2015 - Oct 15 2015

Hong Kong

Research Assistant :: Department of Ophthalmology

Yellow-river Hospital Jul 01 2006 - Aug 01 2010

China

Ophthalmology Resident :: Department of Ophthalmology

Education History

Zhengzhou University Aug 28 2012 - Jun 28 2016

China

PHD :: Department of Ophthalmology

Zhengzhou University Aug 30 2010 - Jul 01 2012

China

MSC :: Department of Ophthalmology

Publications

Rui Zhang, Yalong Dang
The Recent Advances in the Function and Mechanism of Caveolin-1 in Retinal Neovascularization. Current drug targets 25 (7) (2024)
Wanyu Tang, Yalong Dang
In Vivo Models of Steroid-Induced Intraocular Hypertension. Current drug targets (2024)
Rui Zhang, Yalong Dang
The Recent Advances in the Function and Mechanism of Caveolin-1 in Retinal Neovascularization. Current drug targets (2024)
Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Fang Lei
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma. Current drug targets 25 (2) (2024)
Rui Zhang, Yalong Dang
The Recent Advances in the Function and Mechanism of Caveolin-1 in Retinal Neovascularization. Current drug targets 25 (7) (2024)
Xiaohui Cai, Jing Zhao, Yalong Dang
Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study. Reviews on recent clinical trials (2024)
Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Fang Lei
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma. Current drug targets 25 (2) (2024)
Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Fang Lei
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma. Current drug targets (2023)
Xuejiao Li, Haoliang Chen, Yalong Dang
Assessment of macular and peripapillary choroidal thickness in non-arteritic anterior ischemic optic neuropathy: A meta-analysis. Medicine 102 (8) (2023)
Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Fang Lei
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma. Current drug targets (2023)
Jun Wang, Hanke Wang, Yalong Dang
Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy. Ophthalmology and therapy (2023)
Junhui Wu, Jing Wei, Haoliang Chen, Yalong Dang, Fang Lei
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma. Current drug targets (2023)
Jun Wang, Mengling Li, Ziyue Geng, Saadullah Khattak, Xinying Ji, Dong-Dong Wu, Yalong Dang
Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review. Oxidative medicine and cellular longevity 2022 (2022)
Yalong Dang, Susannah Waxman, Chao Wang, Priyal Shah, Ralitsa T Loewen, Nils A Loewen
Intraocular pressure elevation precedes a phagocytosis decline in a model of pigmentary glaucoma. F1000Research 7 (2018)
Yalong Dang, Susannah Waxman, Chao Wang, Priyal Shah, Ralitsa T Loewen, Nils A Loewen
Intraocular pressure elevation precedes a phagocytosis decline in a model of pigmentary glaucoma. F1000Research (2018)

Yalong Dang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yalong Dang